Novartis Financial Results – Q1 2023
Novartis announced the company’s financial results for the first quarter of 2023.
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company
Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.
Novartis in Society Integrated Report 2022
The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders.
Annual Report 2022
This report provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices and contains our operating and financial results, accompanied by audited annual financial statements.
Novartis condemns the war in Ukraine and has been providing humanitarian support, financial donations as well as considerable volumes of medicines to those people impacted by the war.
Novartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
Novartis resumes business in Ukraine
After studying current safety protocols in the country, and on advice which we will regularly review, we have begun to resume business operations remotely to help the war-torn country restore some basic critical business processes.